Liver Transplant Evaluation Tests: What We Check, and Why Each One Matters






Liver Transplant Evaluation Tests: What We Check, and Why Each One Matters

Liver transplant evaluation tests cover far more than the liver: heart, lungs, kidneys, infection and cancer screening, teeth, nutrition and muscle strength. The aim is not to find reasons to refuse you but to find what must be fixed first. In the 536-patient cohort that built the Liver Frailty Index, one in five patients died or was delisted before transplant: frailty, not liver numbers alone, decided it.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai

Key takeaways

  • A transplant evaluation answers two questions, not one: does this patient need a new liver, and can this patient survive the operation and benefit from it. The second question is why the heart, lungs, kidneys and teeth are examined.
  • Every candidate has an echocardiogram; older patients, diabetics and smokers usually need stress testing or coronary imaging as well. Two liver-specific lung disorders — hepatopulmonary syndrome and portopulmonary hypertension — are screened for because one improves after transplant and the other can make it dangerous.
  • Kidney function shapes transplant timing, operative risk and the choice of anti-rejection drugs. Infection and cancer screening matter because immunosuppression lets anything hidden grow.
  • Frailty is measured, not guessed. A three-part test — grip strength, chair stands, balance — predicts waiting-list death independently of MELD, and the AASLD now recommends it in every candidate.
  • One normal result clears nothing. Eligibility is a multidisciplinary decision on the whole picture, and a new finding during evaluation can change the timing without changing the destination.

Patients often expect a few blood tests, a scan and a decision. A transplant evaluation is far more comprehensive than that — because before recommending transplantation, two fundamentally different questions need answering: does this patient need a transplant, and equally, can this patient safely undergo one and actually benefit from it? That means evaluating the whole person, not just the liver — which is how I approach every assessment as a liver transplant specialist in Mumbai.

My preparation checklist for Indian patients and families covers the practical side — what is tested, how registration with the ZTCC works, the two donor routes, prehabilitation and money. This article is its companion. It explains why each system is assessed, what we are looking for, and what happens when the evaluation turns up something nobody expected. Across the 1,000-plus transplants I have been part of (around 300 of them complex), with 92% survival, the thoroughness of this stage has mattered more to outcomes than the skill of any single day in theatre.

Not a checklist — a reason behind every assessment

The work-up spans multiple systems: liver disease severity, cardiovascular fitness, lung function where indicated, kidney function, nutritional status and muscle strength, infection risk, cancer screening, bone health, dental and oral health, psychological and psychiatric readiness, family and social support, vaccination status, medication history, and the patient’s ability to manage long-term follow-up. The framework we follow is the one set out by the American Association for the Study of Liver Diseases and the American Society of Transplantation in 2013, and by the European Association for the Study of the Liver in 2016, adapted to Indian realities such as tuberculosis exposure and living-donor logistics.

The purpose isn’t making the patient pass an exam. It’s identifying anything that could make transplantation unnecessarily dangerous — and correcting it beforehand wherever possible.

The heart matters more than most patients expect

A patient with severe liver disease often assumes the liver is the only organ in question. It isn’t. The heart has to tolerate a many-hour operation, large shifts in blood volume, and the moment the new liver is reperfused — a physiological jolt that an already-strained circulation may not forgive. Cirrhosis itself alters the heart: a high-output state at rest, a blunted response to stress, and in some patients a cardiomyopathy that only declares itself under load.

So everyone has an echocardiogram. Depending on age, symptoms and risk factors — diabetes, smoking, hypertension, a family history, or simply being over fifty — the assessment extends to stress testing, CT coronary imaging or angiography. If a correctable cardiac problem turns up, it may need optimising before transplant proceeds. This is one reason the evaluation can’t be rushed.

The lungs are examined for the same reason and for two liver-specific problems. Hepatopulmonary syndrome is abnormal dilatation of the lung’s blood vessels that lets blood bypass oxygen exchange; it is screened for with oxygen saturation and an arterial blood gas, and confirmed with a contrast (“bubble”) echocardiogram. It is one of the few complications that transplant reliably cures — and in its severe form it raises the priority for one. Portopulmonary hypertension is the opposite kind of problem: raised pressure in the lung arteries, picked up on the same echocardiogram and confirmed by right-heart catheterisation. Untreated and severe, it makes the operation hazardous enough to be a contraindication, which is why it must be found and treated first. Both are covered in the International Liver Transplantation Society’s 2016 guideline.

Kidney function matters just as much

Advanced liver disease can affect the kidneys, and some patients already have renal dysfunction before transplant — from hepatorenal syndrome, from diabetes, from years of diuretics, or from the disease that caused the cirrhosis in the first place. Kidney function influences transplant timing, overall operative risk, medication choices, peri-operative management and post-transplant recovery. The main anti-rejection drugs are themselves hard on the kidneys, so a kidney that is already struggling needs a different plan from the start. In a small number of patients, the question becomes whether the kidney needs replacing along with the liver. Transplantation is managing the patient’s entire physiology, not the liver in isolation.

System by system: what is tested, and why

The table sets out the domains the AASLD/AST and EASL frameworks ask us to cover. The exact list is tailored to the individual — a 32-year-old with Wilson disease and a 64-year-old diabetic smoker with alcohol-related cirrhosis do not need the same cardiac work-up — but no domain is skipped.

SystemTypical testsWhy it matters
Liver disease severityLiver function tests, INR, creatinine, sodium (for MELD/MELD-Na); contrast CT or MRI of the liver and its vessels; upper GI endoscopyEstablishes need and urgency, maps the anatomy the surgeon will join, and looks for liver cancer, which changes priority and sometimes eligibility. See MELD and Child-Pugh explained.
CardiacECG, echocardiogram in all; stress testing, CT coronary angiography or invasive angiography according to age and risk factorsThe heart must tolerate a long operation and reperfusion. Cirrhosis masks coronary disease and causes its own cardiomyopathy. Correctable problems are fixed first.
PulmonaryOxygen saturation, arterial blood gas, contrast echocardiogram; right-heart catheterisation if pulmonary pressures are raised; lung function tests and chest imaging where indicatedHepatopulmonary syndrome is cured by transplant and may raise priority; untreated severe portopulmonary hypertension can make the operation prohibitively dangerous. Hepatic hydrothorax is assessed here too.
RenalCreatinine, estimated GFR, urinalysis and protein, kidney ultrasoundShapes timing, operative risk and immunosuppressant choice; persistent severe dysfunction raises the question of a combined liver–kidney transplant.
Infection screeningHepatitis B and C, HIV, CMV and EBV status, syphilis; tuberculosis screening (a particular concern in India); blood and urine cultures if unwellImmunosuppression lets any hidden infection flare. Latent TB found now is treated; found after transplant it can be lethal.
Cancer screeningAge-appropriate screening — colonoscopy, mammography, cervical screening, prostate assessment; ENT and upper-airway review in smokers and drinkersAn active cancer outside the liver is an exclusion, and immunosuppression accelerates cancers that would otherwise have stayed slow.
Dental and oralDental examination and treatment of caries, abscesses and periodontal diseaseAn abscessed tooth is trivial today and a source of sepsis on immunosuppression. Healing is also uncomplicated now, and complicated afterwards.
PsychosocialPsychiatric and psychological assessment; documented abstinence where alcohol is involved; assessment of caregiver and family supportLifelong tablets and follow-up are what keep the graft alive. Untreated depression, active substance use or no caregiver are addressed before listing, not discovered after.
Nutrition and frailtyDietitian assessment; handgrip strength; Liver Frailty Index (grip, chair stands, balance); muscle mass on CT where availableFrailty predicts waiting-list death independently of MELD and is modifiable. The AASLD 2021 guidance recommends assessing it in every candidate.
Vaccination and boneHepatitis A and B, pneumococcal, influenza and other vaccines as indicated; bone density where risk factors existVaccines work best before immunosuppression and live vaccines cannot be given after. Cirrhosis thins bone; a fracture during the wait is a real risk, as the case below shows.

The assessments patients don’t expect

Dental evaluation. Dental and oral infections matter once a patient is heading into major surgery followed by immunosuppression. “Why are you sending me to a dentist when my liver is failing?” comes up often — the answer is that we’re preparing for the period after transplant, not just the operation itself.

Psychological and psychiatric assessment. A transplant is a lifelong commitment — medicines, monitoring, lifestyle change, repeated appointments. This assessment isn’t about labelling someone “good” or “bad” for transplant. It identifies issues that can be addressed beforehand and makes sure the patient understands what lifelong transplant care actually involves.

Social support. Easy to underestimate. Recovery needs reliable help with medications, appointments, nutrition, transport, daily life. Family isn’t an audience during this process — they’re part of the recovery system.

Vaccination status. Easily overlooked, but immunosuppression after transplant changes how the immune system handles vaccines and infections — so relevant vaccination needs are ideally identified and addressed before, not after.

Muscle and frailty. This is the domain that has changed most in the last decade. Jennifer Lai’s group at San Francisco followed 536 patients listed for transplant and found that three simple bedside tests — handgrip, how fast you can stand from a chair five times, and how long you can hold your balance — predicted death on the waiting list over and above MELD-Na, and correctly reclassified a meaningful share of patients the score alone had got wrong. One in five of those patients died or was delisted. A follow-up study of 529 patients showed the index beat the hepatologist’s own eyeball judgement of who looked frail. The AASLD’s 2021 guidance on malnutrition, frailty and sarcopenia now asks that every candidate be assessed this way. Unlike MELD, frailty is something the patient can change, which is why the dietitian and physiotherapist meet you during evaluation and not after. My guide to protein, sarcopenia and the Indian diet in cirrhosis covers what to do about it.

Why so many tests?

“We are not looking for reasons to reject you. We are looking for reasons to make the transplant safer.” That distinction matters. Evaluation may uncover diabetes, coronary artery disease, kidney dysfunction, malnutrition, an untreated dental problem, or an infection risk. Finding it before transplant gives us a chance to optimise it. Discovering it after can be far harder to manage.

One normal test doesn’t clear you

“My heart test is normal, so I’m fit for transplant” — or “my liver tests improved, so I don’t need the rest of the work-up.” Neither holds. Eligibility isn’t determined by a single test, scan or consult. It is a multidisciplinary decision built on the complete clinical picture: liver disease trajectory, other medical conditions, nutritional and functional status, psychosocial readiness, infection and malignancy risk, and whether the expected benefit outweighs the risk. If your evaluation elsewhere stopped at a single abnormal result, a second opinion on transplant eligibility is reasonable; most abnormal findings are optimised, not treated as a verdict. The companion article on absolute versus reversible contraindications goes through which findings genuinely close the door and which only delay it.

When the evaluation changes the plan: a real case

Evaluation doesn’t always run in a straight line from assessment to surgery. I remember a 54-year-old woman with advanced liver disease, recurrent ascites and recurrent right-sided hepatic hydrothorax being evaluated for transplant. She was already clinically fragile. During evaluation, she developed a right shoulder fracture and deteriorated further.

At that point, the question stopped being “is she a candidate?” and became: how do we make her safe enough to undergo transplantation?

A major operation in a patient with advanced liver disease, recurrent fluid accumulation and a new fracture carries real added risk — to breathing, to mobility, to the ability to rehabilitate afterwards. Rather than rushing to transplant or abandoning the pathway, we brought in the appropriate multidisciplinary team members and worked on optimising her condition: managing the fluid, addressing her medical problems, stabilising her as much as possible, and continuously reassessing fitness. Once sufficiently optimised, she proceeded to transplant. The outcome was good.

Patients sometimes get frustrated when transplant doesn’t happen immediately after the initial evaluation — “if the transplant is needed, why are we waiting?” But transplant medicine isn’t only about deciding whether someone needs a new liver. It’s also about determining when they’re in the best possible condition to undergo the operation. Sometimes that’s an infection to treat first. Sometimes nutrition or muscle strength. Sometimes a cardiac issue. And sometimes, as here, an unexpected event changes the immediate priorities entirely.

The goal was never to delay unnecessarily — it was to optimise her enough that the transplant had the best possible chance of succeeding. She wasn’t simply evaluated for a transplant. She was prepared for one.

The goal isn’t just getting to the operating room

A successful evaluation answers three questions: does the patient need transplantation now or in the foreseeable future; can we make transplantation reasonably safe; and will the patient be able to benefit from it and manage the lifelong care that follows. Once those are answered, timing decisions get made with real clarity — including whether a living donor in the family allows us to choose the date rather than wait for one, and sometimes whether another treatment should come first .

The evaluation can feel exhaustive from the patient’s side. From the transplant team’s side, that thoroughness is the entire point — we’re not preparing only for the day of surgery. We’re preparing for the years of life that should follow it. None of this replaces a conversation with your own transplant team, and no medicine should be started, stopped or altered on the strength of an article; bring your reports and the questions worth asking to the consultation.

Frequently asked questions

How long does the full liver transplant evaluation take?

It varies with individual complexity and how many findings need addressing before clearance. An uncomplicated evaluation can be completed in a few weeks of outpatient visits; one that uncovers a cardiac problem, an infection or severe frailty takes longer because those are treated first. Ask your transplant team for a realistic estimate specific to your case.

Can the evaluation itself change my transplant timing?

Yes. New findings during evaluation — an infection, a cardiac abnormality, a fracture, poor nutrition — can shift the plan, sometimes requiring weeks of optimisation before proceeding. That is a delay in the patient’s interest, not a change of destination.

If one test comes back abnormal, does that disqualify me?

Not automatically. Most abnormal findings are addressed and optimised rather than treated as an outright disqualifier. Only a small group — active cancer outside the liver, uncontrolled infection, severe untreated heart or lung disease, ongoing substance use — are true contraindications, and some of those are reversible.

Why do I need heart tests before a liver transplant?

Because the operation lasts many hours, involves large shifts in blood volume and ends with reperfusion of the new liver — a stress a weak heart may not tolerate. Cirrhosis also hides coronary disease and can cause its own cardiomyopathy. Everyone has an echocardiogram; older patients, diabetics and smokers usually need stress testing or coronary imaging as well.

Why is a dental check-up part of a liver transplant work-up?

Because after transplant your immune system is deliberately suppressed, and a dental abscess that is trivial today can become a serious infection then. Dental work also heals far better before immunosuppression than after.

What is the Liver Frailty Index?

A three-part bedside test — handgrip strength, the time taken to stand from a chair five times, and balance — developed by Jennifer Lai’s group in San Francisco. It predicts death on the waiting list over and above the MELD score, and the AASLD recommends measuring it in every transplant candidate because, unlike MELD, frailty can be improved with nutrition and exercise.

Book a consultation with Dr Chetan Kalal at Gleneagles Hospital, Mumbai — call +91 83294 76669 or use the appointment form on this site. International and NRI patients may request a teleconsultation.

Author: Dr Chetan Kalal — DM Hepatologist, Gleneagles Hospital Mumbai. ORCID: https://orcid.org/0000-0002-5284-7890

Last reviewed: 14 October 2026

Related reading

References

  1. Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144–1165. PMID 24716201. doi:10.1002/hep.26972
  2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64(2):433–485. PMID 26597456. doi:10.1016/j.jhep.2015.10.006
  3. Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation. 2016;100(7):1440–1452. PMID 27326810. doi:10.1097/TP.0000000000001229
  4. Lai JC, Covinsky KE, Dodge JL, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology. 2017;66(2):564–574. PMID 28422306. doi:10.1002/hep.29219
  5. Lai JC, Covinsky KE, McCulloch CE, Feng S. The Liver Frailty Index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol. 2018;113(2):235–242. PMID 29231189. doi:10.1038/ajg.2017.443
  6. Lai JC, Tandon P, Bernal W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(3):1611–1644. PMID 34233031. doi:10.1002/hep.32049

Leave a Comment

Your email address will not be published. Required fields are marked *

About

Dr. Chetan Kalal is a DM Hepatologist with 15+ years of experience in managing liver diseases, advanced liver conditions and liver transplant-related care. He currently serves as Associate Director, Hepatology & Liver Transplant at Gleneagles Hospital, Mumbai.

Reach Out To Us

Phone: +91-83294 76669
Email: dr.chetankalal@gmail.com
Location: OPD 205, Gleneagles Hospital, Dr Ernest Borges Road, Opp. Shirodkar High School, Parel East, Mumbai, Maharashtra 400012,

Dr Chetan Ramesh Kalal · MBBS, MD (Medicine), DM (Hepatology) · Reg. No. 2007/04/0848, Maharashtra Medical Council

Copyright © 2026 DR. CHETAN KALAL | DESIGNED BY EEG TECHNOGEEKS

Where Dr. Chetan Raameshh Kalal consults

DM Hepatology (ILBS, New Delhi) · MD Medicine (Seth GS Medical College & KEM Hospital, Mumbai) · first DM hepatologist of Maharashtra · Associate Director, Hepatology & Liver Transplant, Gleneagles Hospital Mumbai

Dr. Kalal is a hepatologist and liver transplant physician in Mumbai. He sees patients at five locations across the city:

Appointments and second opinions: +91 83294 76669 · WhatsApp · Online video consultation available. ORCID 0000-0002-5284-7890

Scroll to Top